Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
News Medical on MSN8h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial showsSotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
News Medical on MSN21h
A step toward precision medicine: New drug targets for heart failureA groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...
The best-known class of medications that impact LDL-C have been the statins which have universally demonstrated reduced cardiovascular events in adequately treated patients. That means fewer heart ...
An existing cardiac drug has now been found to reduce the risk of metastasis by dissolving circulating clusters of breast cancer cells in patients. SUBSCRIBE AD-FREE LOG IN ...
A drug commonly used to treat high blood pressure, nifedipine, may pose more risks than previously thought, according to a ...
Numbers released by the Heart Failure Society of America in September 2024 reveal that approximately 6.7 million Americans ...
For a long time, there have been concerns that beta-blockers might cause mental health problems like depression, anxiety, and ...
New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback